1. Home
  2. GMRS vs ASMB Comparison

GMRS vs ASMB Comparison

Compare GMRS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GMRS

GMR Solutions Inc. Class A Common Stock

N/A

Current Price

$11.17

Market Cap

551.0M

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$20.11

Market Cap

512.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GMRS
ASMB
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
551.0M
512.1M
IPO Year
2026
2010

Fundamental Metrics

Financial Performance
Metric
GMRS
ASMB
Price
$11.17
$20.11
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$18.63
★ $52.00
AVG Volume (30 Days)
★ 726.6K
199.6K
Earning Date
11-09-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.78
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$5.13
N/A
Revenue Next Year
$5.57
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.00
$19.30
52 Week High
$15.98
$39.71

Technical Indicators

Market Signals
Indicator
GMRS
ASMB
Relative Strength Index (RSI) 55.70 35.67
Support Level $9.75 $19.30
Resistance Level $14.14 $21.93
Average True Range (ATR) 0.51 1.02
MACD 0.19 0.26
Stochastic Oscillator 74.45 23.05

Price Performance

Historical Comparison
GMRS
ASMB

About GMRS GMR Solutions Inc. Class A Common Stock

GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: